Starling Oncology investor deck: FY26 revenue guided to $650-660M after OrbiMed refinancing and rebrand

Starling Oncology, a value-based oncology care and benefits management company now trading on Nasdaq as STLN, issued an investor presentation dated November 2026. It cites Q3 2026 revenue of $170M (up 24% year over year), FY26 revenue guidance of $650-660M and Adjusted EBITDA of $4-6M. It also covers repayment of an $86M Deerfield note through an OrbiMed refinancing, 2.2M+ value-based care lives, and growth in capitated contracts outside California.

12 Nov 2026 · Starling Oncology, Inc. DFPH · Company news

Company's press release (SEC filing): Starling Oncology, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

Starling Oncology investor deck: FY26 revenue guided to $650-660M after OrbiMed refinancing and rebrand

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq